JO
KRTX

John Overdeck’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

John Overdeck’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,556
Closed -$432K – 3446
2023
Q3 		$432K Sell
2,556
-4,580
-64% -$861K ﹤0.01% 2338
2023
Q2 		$1.55M Buy
7,136
+33
+0.5% +$7.07K ﹤0.01% 1662
2023
Q1 		$1.29M Sell
7,103
-100,737
-93% -$19.3M ﹤0.01% 1728
2022
Q4 		$21.2M Sell
107,840
-102,122
-49% -$21.9M 0.07% 340
2022
Q3 		$47.2M Buy
+209,962
New +$42.5M 0.16% 160
2021
Q4 		– Sell
-14,700
Closed -$1.8M – 5045
2021
Q3 		$1.8M Sell
14,700
-8,803
-37% -$1.02M ﹤0.01% 2089
2021
Q2 		$2.68M Buy
+23,503
New +$2.75M 0.01% 1640
2021
Q1 		– Sell
-6,742
Closed -$685K – 4347
2020
Q4 		$685K Sell
6,742
-32,264
-83% -$2.99M ﹤0.01% 2276
2020
Q3 		$3.02M Buy
39,006
+28,159
+260% +$2.4M 0.01% 1062
2020
Q2 		$1.21M Buy
+10,847
New +$943K 0.01% 1413

Other funds holding KRTX

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

John Overdeck's KRTX Position: Q4 2023 in Review

John Overdeck sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 2,556 shares — an estimated $432K sold.

John Overdeck first reported a position in KRTX in Q2 2020 and held it in 10 quarters. The position peaked at $47.2M in Q3 2022. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

  • John Overdeck reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • John Overdeck sold 2,556 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $432K.
  • John Overdeck first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • John Overdeck's Karuna Therapeutics, Inc. Common Stock position peaked at $47.2M in Q3 2022.
  • 328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.